<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028483</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069079</org_study_id>
    <secondary_id>SGEN-UAB-9912</secondary_id>
    <secondary_id>UAB-9912</secondary_id>
    <nct_id>NCT00028483</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer</brief_title>
  <official_title>A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Monoclonal antibodies can locate tumor cells and deliver&#xD;
      tumor-killing substances to them without harming normal cells. Combining chemotherapy with&#xD;
      monoclonal antibody therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and monoclonal&#xD;
      antibody therapy in treating women who have metastatic or recurrent breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity and safety profile of doxorubicin-monoclonal antibody BR96&#xD;
           immunoconjugate (SGN-15) and docetaxel in women with metastatic or recurrent breast&#xD;
           cancer.&#xD;
&#xD;
        -  Determine the clinical response rate and duration of response of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive doxorubicin-monoclonal antibody BR96 immunoconjugate (SGN-15) IV&#xD;
      over 2 hours and docetaxel IV over 30 minutes on day 1 of weeks 1-6. Treatment repeats every&#xD;
      8 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 45 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cBR96-doxorubicin immunoconjugate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic or recurrent breast carcinoma&#xD;
&#xD;
               -  Unresectable disease&#xD;
&#xD;
               -  Previously treated with no more than 2 chemotherapy regimens for metastatic&#xD;
                  disease OR&#xD;
&#xD;
               -  Recurrent within 6 months of adjuvant chemotherapy&#xD;
&#xD;
          -  Must have one of the following:&#xD;
&#xD;
               -  Measurable disease&#xD;
&#xD;
               -  Positive bone scan and elevation of serum tumor marker for adenocarcinoma&#xD;
&#xD;
                    -  Serum levels must have increased over 2 consecutive measurements and exceed&#xD;
                       at least 2 times upper limit of normal&#xD;
&#xD;
          -  Lewis-y antigen expression documented by immunohistochemistry&#xD;
&#xD;
          -  No brain metastases that are uncontrolled or require active treatment (including&#xD;
             steroids)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 2.5 times normal&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times normal (unless documented bony&#xD;
             metastasis present)&#xD;
&#xD;
          -  Amylase/lipase less than 1.5 times normal&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
          -  No hepatic failure&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times upper limit of normal&#xD;
&#xD;
          -  No renal failure&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF greater than 50% by echocardiogram or MUGA scan&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No antibody present that detects monoclonal antibody BR96 in serum&#xD;
&#xD;
          -  No peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  No dementia or altered mental status&#xD;
&#xD;
          -  No other serious underlying medical condition that would preclude study participation&#xD;
&#xD;
          -  No prior allergic reactions to recombinant human or murine proteins&#xD;
&#xD;
          -  No uncontrolled peptic ulcer disease&#xD;
&#xD;
          -  No active viral, bacterial, or systemic fungal infections&#xD;
&#xD;
          -  No other primary malignancy except nonmelanoma skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No serious nonmalignant disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 8 weeks since prior therapeutic or diagnostic murine/humanized/human chimeric&#xD;
             antibodies&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin,&#xD;
             mitomycin, or anthracyclines)&#xD;
&#xD;
          -  No prior cumulative anthracycline of 300 mg/m2 or more&#xD;
&#xD;
          -  No concurrent antineoplastic agents&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy except estrogen replacement&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent experimental agents&#xD;
&#xD;
          -  No concurrent immunosuppressive medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisle M. Nabell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>June 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2003</study_first_posted>
  <last_update_submitted>October 21, 2011</last_update_submitted>
  <last_update_submitted_qc>October 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2011</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

